UniProt ID | PSA4_HUMAN | |
---|---|---|
UniProt AC | P25789 | |
Protein Name | Proteasome subunit alpha type-4 | |
Gene Name | PSMA4 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 261 | |
Subcellular Localization | Cytoplasm . Nucleus . Colocalizes with TRIM5 in the cytoplasmic bodies. | |
Protein Description | Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).. | |
Protein Sequence | MSRRYDSRTTIFSPEGRLYQVEYAMEAIGHAGTCLGILANDGVLLAAERRNIHKLLDEVFFSEKIYKLNEDMACSVAGITSDANVLTNELRLIAQRYLLQYQEPIPCEQLVTALCDIKQAYTQFGGKRPFGVSLLYIGWDKHYGFQLYQSDPSGNYGGWKATCIGNNSAAAVSMLKQDYKEGEMTLKSALALAIKVLNKTMDVSKLSAEKVEIATLTRENGKTVIRVLKQKEVEQLIKKHEEEEAKAEREKKEKEQKEKDK | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Phosphorylation | ------MSRRYDSRT ------CCCCCCCCC | 26.01 | 26074081 | |
5 | Phosphorylation | ---MSRRYDSRTTIF ---CCCCCCCCCEEE | 19.70 | 28555341 | |
7 | Phosphorylation | -MSRRYDSRTTIFSP -CCCCCCCCCEEECC | 23.69 | 30622161 | |
9 | Phosphorylation | SRRYDSRTTIFSPEG CCCCCCCCEEECCCC | 28.35 | 23927012 | |
10 | Phosphorylation | RRYDSRTTIFSPEGR CCCCCCCEEECCCCC | 20.93 | 23927012 | |
13 | Phosphorylation | DSRTTIFSPEGRLYQ CCCCEEECCCCCEEE | 20.42 | 19664994 | |
54 | Acetylation | AERRNIHKLLDEVFF HHHCCHHHHHHHHHH | 47.12 | 25953088 | |
54 | Ubiquitination | AERRNIHKLLDEVFF HHHCCHHHHHHHHHH | 47.12 | 21890473 | |
54 | 2-Hydroxyisobutyrylation | AERRNIHKLLDEVFF HHHCCHHHHHHHHHH | 47.12 | - | |
56 | Acetylation | RRNIHKLLDEVFFSE HCCHHHHHHHHHHCH | 6.69 | 19608861 | |
56 | Ubiquitination | RRNIHKLLDEVFFSE HCCHHHHHHHHHHCH | 6.69 | 19608861 | |
62 | Phosphorylation | LLDEVFFSEKIYKLN HHHHHHHCHHHHHCC | 26.90 | 21712546 | |
64 | Ubiquitination | DEVFFSEKIYKLNED HHHHHCHHHHHCCCC | 50.57 | 21890473 | |
64 | 2-Hydroxyisobutyrylation | DEVFFSEKIYKLNED HHHHHCHHHHHCCCC | 50.57 | - | |
67 | Ubiquitination | FFSEKIYKLNEDMAC HHCHHHHHCCCCCCC | 48.59 | 21906983 | |
72 | Sulfoxidation | IYKLNEDMACSVAGI HHHCCCCCCCHHHCC | 3.10 | 30846556 | |
74 | Glutathionylation | KLNEDMACSVAGITS HCCCCCCCHHHCCCC | 2.42 | 22555962 | |
75 | Phosphorylation | LNEDMACSVAGITSD CCCCCCCHHHCCCCC | 12.88 | 20068231 | |
80 | Phosphorylation | ACSVAGITSDANVLT CCHHHCCCCCHHHHH | 21.45 | 20068231 | |
81 | Phosphorylation | CSVAGITSDANVLTN CHHHCCCCCHHHHHH | 32.57 | 20068231 | |
87 | Phosphorylation | TSDANVLTNELRLIA CCCHHHHHHHHHHHH | 23.51 | 20068231 | |
105 | Ubiquitination | LLQYQEPIPCEQLVT HHHCCCCCCHHHHHH | 6.32 | 19608861 | |
105 | Acetylation | LLQYQEPIPCEQLVT HHHCCCCCCHHHHHH | 6.32 | 19608861 | |
105 | Ubiquitination | LLQYQEPIPCEQLVT HHHCCCCCCHHHHHH | 6.32 | 21890473 | |
121 | Phosphorylation | LCDIKQAYTQFGGKR HHHHHHHHHHHCCCC | 9.89 | 28152594 | |
122 | Phosphorylation | CDIKQAYTQFGGKRP HHHHHHHHHHCCCCC | 22.04 | 28152594 | |
127 | Ubiquitination | AYTQFGGKRPFGVSL HHHHHCCCCCCCEEE | 58.22 | 19608861 | |
127 | Sumoylation | AYTQFGGKRPFGVSL HHHHHCCCCCCCEEE | 58.22 | 19608861 | |
127 | Acetylation | AYTQFGGKRPFGVSL HHHHHCCCCCCCEEE | 58.22 | 19608861 | |
128 | Ubiquitination | YTQFGGKRPFGVSLL HHHHCCCCCCCEEEE | 34.75 | 21890473 | |
134 | Ubiquitination | KRPFGVSLLYIGWDK CCCCCEEEEEEEECC | 3.80 | 21890473 | |
139 | Ubiquitination | VSLLYIGWDKHYGFQ EEEEEEEECCCCCEE | 11.26 | 21890473 | |
143 | Phosphorylation | YIGWDKHYGFQLYQS EEEECCCCCEEEEEC | 25.94 | - | |
148 | Phosphorylation | KHYGFQLYQSDPSGN CCCCEEEEECCCCCC | 8.66 | 29496907 | |
156 | Phosphorylation | QSDPSGNYGGWKATC ECCCCCCCCCEEEEE | 22.12 | 29496907 | |
160 | Sumoylation | SGNYGGWKATCIGNN CCCCCCEEEEEECCC | 36.77 | - | |
160 | Ubiquitination | SGNYGGWKATCIGNN CCCCCCEEEEEECCC | 36.77 | - | |
160 | Acetylation | SGNYGGWKATCIGNN CCCCCCEEEEEECCC | 36.77 | 68717 | |
160 | Ubiquitination | SGNYGGWKATCIGNN CCCCCCEEEEEECCC | 36.77 | 21890473 | |
162 | Phosphorylation | NYGGWKATCIGNNSA CCCCEEEEEECCCHH | 10.83 | 21406692 | |
167 | Ubiquitination | KATCIGNNSAAAVSM EEEEECCCHHHHHHH | 28.01 | 19608861 | |
167 | Ubiquitination | KATCIGNNSAAAVSM EEEEECCCHHHHHHH | 28.01 | 21890473 | |
167 | Acetylation | KATCIGNNSAAAVSM EEEEECCCHHHHHHH | 28.01 | 19608861 | |
168 | Phosphorylation | ATCIGNNSAAAVSML EEEECCCHHHHHHHH | 24.24 | 21406692 | |
173 | Phosphorylation | NNSAAAVSMLKQDYK CCHHHHHHHHHCCHH | 17.42 | 25159151 | |
174 | Sulfoxidation | NSAAAVSMLKQDYKE CHHHHHHHHHCCHHH | 4.33 | 21406390 | |
176 | Acetylation | AAAVSMLKQDYKEGE HHHHHHHHCCHHHCC | 32.26 | 19608861 | |
176 | Ubiquitination | AAAVSMLKQDYKEGE HHHHHHHHCCHHHCC | 32.26 | 21890473 | |
180 | Succinylation | SMLKQDYKEGEMTLK HHHHCCHHHCCCCHH | 68.48 | 23954790 | |
180 | Acetylation | SMLKQDYKEGEMTLK HHHHCCHHHCCCCHH | 68.48 | 25953088 | |
180 | Ubiquitination | SMLKQDYKEGEMTLK HHHHCCHHHCCCCHH | 68.48 | - | |
187 | Ubiquitination | KEGEMTLKSALALAI HHCCCCHHHHHHHHH | 25.23 | 21906983 | |
188 | Phosphorylation | EGEMTLKSALALAIK HCCCCHHHHHHHHHH | 31.46 | 23312004 | |
195 | 2-Hydroxyisobutyrylation | SALALAIKVLNKTMD HHHHHHHHHHHCCCC | 34.75 | - | |
195 | Acetylation | SALALAIKVLNKTMD HHHHHHHHHHHCCCC | 34.75 | 25953088 | |
195 | Ubiquitination | SALALAIKVLNKTMD HHHHHHHHHHHCCCC | 34.75 | - | |
199 | Acetylation | LAIKVLNKTMDVSKL HHHHHHHCCCCHHHH | 40.85 | 26822725 | |
199 | Ubiquitination | LAIKVLNKTMDVSKL HHHHHHHCCCCHHHH | 40.85 | 21890473 | |
205 | 2-Hydroxyisobutyrylation | NKTMDVSKLSAEKVE HCCCCHHHHCHHHEE | 46.43 | - | |
205 | Ubiquitination | NKTMDVSKLSAEKVE HCCCCHHHHCHHHEE | 46.43 | 21906983 | |
205 | Acetylation | NKTMDVSKLSAEKVE HCCCCHHHHCHHHEE | 46.43 | 25953088 | |
207 | Phosphorylation | TMDVSKLSAEKVEIA CCCHHHHCHHHEEEE | 37.81 | 26091039 | |
210 | Ubiquitination | VSKLSAEKVEIATLT HHHHCHHHEEEEEEE | 44.90 | 21890473 | |
210 | Acetylation | VSKLSAEKVEIATLT HHHHCHHHEEEEEEE | 44.90 | 23749302 | |
215 | Phosphorylation | AEKVEIATLTRENGK HHHEEEEEEEECCCE | 34.03 | 21406692 | |
217 | Phosphorylation | KVEIATLTRENGKTV HEEEEEEEECCCEEE | 31.42 | 21406692 | |
222 | Ubiquitination | TLTRENGKTVIRVLK EEEECCCEEEEEEEC | 51.72 | - | |
222 | Acetylation | TLTRENGKTVIRVLK EEEECCCEEEEEEEC | 51.72 | 25953088 | |
223 | Phosphorylation | LTRENGKTVIRVLKQ EEECCCEEEEEEECH | 23.67 | - | |
229 | Ubiquitination | KTVIRVLKQKEVEQL EEEEEEECHHHHHHH | 57.37 | - | |
231 | Ubiquitination | VIRVLKQKEVEQLIK EEEEECHHHHHHHHH | 63.24 | 21890473 | |
231 | Malonylation | VIRVLKQKEVEQLIK EEEEECHHHHHHHHH | 63.24 | 26320211 | |
231 | Acetylation | VIRVLKQKEVEQLIK EEEEECHHHHHHHHH | 63.24 | 23749302 | |
238 | Ubiquitination | KEVEQLIKKHEEEEA HHHHHHHHHHHHHHH | 57.58 | 21906983 | |
238 | Acetylation | KEVEQLIKKHEEEEA HHHHHHHHHHHHHHH | 57.58 | 19608861 | |
246 | Ubiquitination | KHEEEEAKAEREKKE HHHHHHHHHHHHHHH | 54.80 | 2190698 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PSA4_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PSA4_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PSA4_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-127; LYS-176 AND LYS-238,AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND MASSSPECTROMETRY. | |
"Mass spectrometric characterization of the affinity-purified human26S proteasome complex."; Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.; Biochemistry 46:3553-3565(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-75, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND MASSSPECTROMETRY. |